With more than 20 supported items and a few being worked on, the Avastin® biosimilars market is projected to observe essential development throughout the next few years, claims Roots Analysis
In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe,…